ARX788 in HER2-positive Metastatic Breast Cancer Patients
A phase 2 study of ARX788 given every 6 weeks in HER2-positive, metastatic breast cancer patients.
Trial Details
- NCT ID
- NCT06663748
- Phase
- PHASE2
- Sponsor
- Henan Cancer Hospital
- Status
- RECRUITING
- Cancer Type
- Breast Cancer
- Interventions
- Locations (sample)
- Zhengzhou, Henan, China|34.75778,113.64861
Key Eligibility Criteria
- 18 to 75 years old (including upper and lower limits), male or female;
- Unresectable locally advanced, recurrent or metastatic BC;
- Has previously received ≤ two lines of chemotherapy (excluding hormone therapy) for recurrent or metastatic BC;
- Tissue samples determined to be HER2 positive (defined as IHC3+ or FISH+);
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →